Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer

In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab.(1) This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.

Detalles Bibliográficos
Autores principales: Makhlin, Igor, DeMichele, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245054/
https://www.ncbi.nlm.nih.gov/pubmed/35732147
http://dx.doi.org/10.1016/j.xcrm.2022.100668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245054/
https://www.ncbi.nlm.nih.gov/pubmed/35732147
http://dx.doi.org/10.1016/j.xcrm.2022.100668

Ejemplares similares